|Articles|October 12, 2021
Pharmacy Clinical Pearl of the Day: Familial Hypercholesterolemia
Author(s)Saro Arakelians, PharmD
People who inherit familial hypercholesterolemia from both parents usually develop symptoms in childhood.
Advertisement
Clinical Pearl of the Day: Familial Hypercholesterolemia
Familial hypercholesterolemia, is genetic disorder, causing having a very high cholesterol level, which affects the way the body processes cholesterol.
Insight:
- The genetic changes that cause familial hypercholesterolemia are inherited. The condition is present from birth, but symptoms may not appear until adulthood.
- People who inherit the condition from both parents usually develop symptoms in childhood. If this rare and more severe variety is left untreated, death often occurs before age 20.
- Symptoms may include negative impact on skin occurring on the hands, elbows and knees; thickening tendons, including the Achilles tendon; and it can affect the eyes.
- Familial hypercholesterolemia may be more common in certain populations, including Ashkenazi Jews, some Lebanese groups, and French Canadians.
- Diagnosis may include a cholesterol test and genetic test.
- Treatment may include statins, such as atorvastatin (Lipitor), fluvastatin (Lescol XL), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin, rosuvastatin (Crestor) and simvastatin (Zocor), ezetimibe (Zetia) and PCSK9 inhibitors such as alirocumab (Praluent) and evolocumab (Repatha).
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5